Celastrol inhibits tat-mediated human immunodeficiency virus (HIV) transcription and replication

Journal of Molecular Biology

Volumn 410, Issue 5, 2011, Pages 972-983

  Narayan, Vivek ^a   Ravindra, Kodihalli C ^a   Chiaro, Chris ^a   Cary, Daniele ^b   Aggarwal, Bharat B ^c   Henderson, Andrew J ^b   Prabhu, K Sandeep ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cys domain; interaction; Michael acceptors; natural products

Indexed keywords

CELASTROL; CURCUMIN; GAMBOGIC ACID; ROSMARINIC ACID; TRANSACTIVATOR PROTEIN;

ALKYLATION; ANTIVIRAL ACTIVITY; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; ELECTROPHILICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY; TRIPTERYGIUM WILFORDII; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; TRIPTERYGIUM WILFORDII;

EID: 79960351591     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.04.013     Document Type: Article

References (51)

1. Agbottah E.; Deng L.; Dannenberg L.O.; Pumfery A.; and Kashanchi F. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription Retrovirology 3 2006 48
2. Mahmoudi T.; Parra M.; Vries R.G.; Kauder S.E.; Verrijzer C.P.; Ott M.; and Verdin E. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter J. Biol. Chem. 281 2006 19960 19968 (Pubitemid 44065769)
3. Pierson T.; McArthur J.; and Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy Annu. Rev. Immunol. 18 2000 665 708 (Pubitemid 30365394)
4. Rohr O.; Marban C.; Aunis D.; and Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells J. Leukoc. Biol. 74 2003 736 749 (Pubitemid 38040350)
5. Marciniak R.A.; Calnan B.J.; Frankel A.D.; and Sharp P.A. HIV-1 Tat protein trans-activates transcription in vitro Cell 63 1990 791 802 (Pubitemid 120035052)
6. Feinberg M.B.; Baltimore D.; and Frankel A.D. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation Proc. Natl Acad. Sci. USA 88 1991 4045 4049 (Pubitemid 21916761)
7. Karn J. Tackling Tat J. Mol. Biol. 293 1999 235 254 (Pubitemid 29516167)
8. Sodroski J.; Rosen C.; Wong-Staal F.; Salahuddin S.Z.; Popovic M.; and Arya S. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat Science 227 1985 171 173 (Pubitemid 15154221)
9. Dingwall C.; Ernberg I.; Gait M.J.; Green S.M.; Heaphy S.; and Karn J. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro Proc. Natl Acad. Sci. USA 86 1989 6925 6929 (Pubitemid 19240844)
10. Weeks K.M.; Ampe C.; Schultz S.C.; Steitz T.A.; and Crothers D.M. Fragments of the HIV-1 Tat protein specifically bind TAR RNA Science 249 1990 1281 1285
11. Garber M.E.; Wei P.; and Jones K.A. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA Cold Spring Harbor Symp. Quant. Biol. 63 1998 371 380 (Pubitemid 29282182)
12. Bourgeois C.F.; Kim Y.K.; Churcher M.J.; West M.J.; and Karn J. Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences Mol. Cell. Biol. 22 2002 1079 1093 (Pubitemid 34094845)
13. Ivanov D.; Kwak Y.T.; Guo J.; and Gaynor R.B. Domains in the SPT5 protein that modulate its transcriptional regulatory properties Mol. Cell. Biol. 20 2000 2970 2983 (Pubitemid 30215010)
14. Ping Y.H.; Chu C.Y.; Cao H.; Jacque J.M.; Stevenson M.; and Rana T.M. Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5 Retrovirology 1 2004 46
15. Ping Y.H.; and Rana T.M. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation J. Biol. Chem. 276 2001 12951 12958
16. Kao S.Y.; Calman A.F.; Luciw P.A.; and Peterlin B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product Nature 330 1987 489 493 (Pubitemid 18006431)
17. Marciniak R.A.; and Sharp P.A. HIV-1 Tat protein promotes formation of more-processive elongation complexes EMBO J. 10 1991 4189 4196 (Pubitemid 21905451)
18. Kessler M.; and Mathews M.B. Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication Proc. Natl Acad. Sci. USA 88 1991 10018 10022 (Pubitemid 21915766)
19. Zhang Z.; Klatt A.; Gilmour D.S.; and Henderson A.J. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex J. Biol. Chem. 282 2007 16981 16988 (Pubitemid 47093194)
20. Laspia M.F.; Rice A.P.; and Mathews M.B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation Cell 59 1989 283 292 (Pubitemid 19264374)
21. GER TAR sequences J. Biomed. Sci. 3 1996 31 40
22. Kuppuswamy M.; Subramanian T.; Srinivasan A.; and Chinnadurai G. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis Nucleic Acids Res. 17 1989 3551 3561 (Pubitemid 19120452)
23. Kalantari P.; Narayan V.; Natarajan S.K.; Muralidhar K.; Gandhi U.H.; and Vunta H. Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophages J. Biol. Chem. 283 2008 33183 33190
24. Kirsch T.; Boehm M.; Schuckert O.; Metzger A.U.; Willbold D.; Frank R.W.; and Rosch P. Cloning, high-yield expression in Escherichia coli, and purification of biologically active HIV-1 Tat protein Protein Expression Purif. 8 1996 75 84 (Pubitemid 26326215)
25. Koken S.E.; Greijer A.E.; Verhoef K.; van Wamel J.; Bukrinskaya A.G.; and Berkhout B. Intracellular analysis of in vitro modified HIV Tat protein J. Biol. Chem. 269 1994 8366 8375 (Pubitemid 24200255)
26. Cuzin L.; Allavena C.; Morlat P.; and Dellamonica P. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? AIDS Rev. 10 2008 205 211
27. Mandas A.; Iorio E.L.; Congiu M.G.; Balestrieri C.; Mereu A.; and Cau D. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy J. Biomed. Biotechnol. 2009 2009 749575
28. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy Prog. Lipid Res. 41 2002 27 65 (Pubitemid 32994811)
29. Asres K.; Seyoum A.; Veeresham C.; Bucar F.; and Gibbons S. Naturally derived anti-HIV agents Phytother. Res. 19 2005 557 581 (Pubitemid 41375238)
30. Bedoya L.M.; Palomino S.S.; Abad M.J.; Bermejo P.; and Alcami J. Screening of selected plant extracts for in vitro inhibitory activity on human immunodeficiency virus Phytother. Res. 16 2002 550 554
31. Bedoya L.M.; Sanchez-Palomino S.; Abad M.J.; Bermejo P.; and Alcami J. Anti-HIV activity of medicinal plant extracts J. Ethnopharmacol. 77 2001 113 116 (Pubitemid 32727754)
32. Barthelemy S.; Vergnes L.; Moynier M.; Guyot D.; Labidalle S.; and Bahraoui E. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat Res. Virol. 149 1998 43 52 (Pubitemid 28162429)
33. De Clercq E. Identification of the real molecular target for HIV inhibitors Trends Pharmacol. Sci. 21 2000 167 168 (Pubitemid 30243195)
34. Dubois M.; Bailly F.; Mbemba G.; Mouscadet J.F.; Debyser Z.; Witvrouw M.; and Cotelle P. Reaction of rosmarinic acid with nitrite ions in acidic conditions: discovery of nitro- and dinitrorosmarinic acids as new anti-HIV-1 agents J. Med. Chem. 51 2008 2575 2579 (Pubitemid 351628520)
35. Pommier Y.; Johnson A.A.; and Marchand C. Integrase inhibitors to treat HIV/AIDS Nat. Rev.; Drug Discov. 4 2005 236 248 (Pubitemid 40372557)
36. Vajragupta O.; Boonchoong P.; Morris G.M.; and Olson A.J. Active site binding modes of curcumin in HIV-1 protease and integrase Bioorg. Med. Chem. Lett. 15 2005 3364 3368 (Pubitemid 40835737)
37. Tewtrakul S.; Miyashiro H.; Nakamura N.; Hattori M.; Kawahata T.; and Otake T. HIV-1 integrase inhibitory substances from Coleus parvifolius Phytother. Res. 17 2003 232 239 (Pubitemid 36406753)
38. 2 inhibits HIV-1 transactivating protein, Tat, through covalent modification FASEB J. 23 2009 2366 2373
39. Salminen A.; Lehtonen M.; Paimela T.; and Kaarniranta K. Celastrol: molecular targets of Thunder God Vine Biochem. Biophys. Res. Commun. 394 2010 439 442
40. Duh E.J.; Maury W.J.; Folks T.M.; Fauci A.S.; and Rabson A.B. Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat Proc. Natl Acad. Sci. USA 86 1989 5974 5978 (Pubitemid 19217570)
41. Osborn L.; Kunkel S.; and Nabel G.J. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB Proc. Natl Acad. Sci. USA 86 1989 2336 2340 (Pubitemid 19102503)
42. Hamma T.; Saleh A.; Huq I.; Rana T.M.; and Miller P.S. Inhibition of HIV tat-TAR interactions by an antisense oligo-2′-O-methylribonucleoside methylphosphonate Bioorg. Med. Chem. Lett. 13 2003 1845 1848 (Pubitemid 36577125)
43. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit J. Biol. Chem. 276 2001 35530 35536
44. Palempalli U.D.; Gandhi U.; Kalantari P.; Vunta H.; Arner R.J.; and Narayan V. Gambogic acid covalently modifies IκB kinase-β subunit to mediate suppression of lipopolysaccharide-induced activation of NF-κB in macrophages Biochem. J. 419 2009 401 409
45. 2 by nuclear factor-kappa B and other cellular proteins Bioorg. Med. Chem. Lett. 15 2005 4057 4063 (Pubitemid 41132661)
46. 2 J. Biol. Chem. 278 2003 51251 51260 (Pubitemid 38020362)
47. Perez-Sala D.; Cernuda-Morollon E.; Pineda-Molina E.; and Canada F.J. Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins Ann. N. Y. Acad. Sci. 973 2002 533 536 (Pubitemid 36125064)
48. Rossi A.; Kapahi P.; Natoli G.; Takahashi T.; Chen Y.; Karin M.; and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase Nature 403 2000 103 108 (Pubitemid 30038530)
49. Shibata T.; Yamada T.; Ishii T.; Kumazawa S.; Nakamura H.; and Masutani H. Thioredoxin as a molecular target of cyclopentenone prostaglandins J. Biol. Chem. 278 2003 26046 26054 (Pubitemid 36835372)
50. Henderson A.J.; Zou X.; and Calame K.L. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes J. Virol. 69 1995 5337 5344
51. Patki A.H.; and Lederman M.M. HIV-1 Tat protein and its inhibitor Ro 24-7429 inhibit lymphocyte proliferation and induce apoptosis in peripheral blood mononuclear cells from healthy donors Cell. Immunol. 169 1996 40 46 (Pubitemid 26124614)